📉 Live Chart
Interactive · powered by TradingView
📊 marketbrief Score For reference
Our own score derived from public financial data, ranked against sector peers. Updated daily.
3.1
/ 5.0
Hold
Grade B-, ranked against 60 peers in the Healthcare sector.
Valuation가치
C+
Growth성장
B
Profitability수익성
B-
Momentum모멘텀
B
※ This score is informational only and not investment advice. See the methodology page for the formula. Methodology →
✍️ marketbrief View
Thermo Fisher Scientific supplies lab equipment and reagents for research, so its results track overall pharma and biotech R&D spending rather than any single drug's success. Both growth (B-) and profitability (B-) are solid but unremarkable.
Momentum (B+) has been relatively strong lately, which can be read as a signal that pharma R&D spending is picking back up. Valuation (C+, ~33x P/E) sits in a middling range — neither especially cheap nor expensive.
Key Stats
As of last close
Market Cap
$266.1B
PER
37.9
Dividend Yield
0.26%
52-Week High
$723.08
52-Week Low
$435.27
1-Year Return
+24.1%